Literature DB >> 22647364

Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis.

Mattia Boeri1, Ugo Pastorino, Gabriella Sozzi.   

Abstract

Lung cancer-related mortality is the most common cause of cancer death worldwide. Detecting lung cancer at an earlier stage and, ideally, predicting who will develop the disease and particularly the most aggressive forms of cancer are the biggest challenge. MicroRNAs (miRNAs) are short, noncoding RNA molecules with regulatory function on protein-coding genes. Because of their fundamental role in development and differentiation, their involvement in the biological mechanisms underlying tumorigenesis, as well as their low complexity, stability, and easy detection, they represent a promising class of tissue- and blood-based biomarkers of cancer. We summarize the current literature on the use of microRNAs as diagnostic and prognostic tools in lung cancer and discuss the relevant clinical implications of these findings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22647364     DOI: 10.1097/PPO.0b013e318258b743

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  48 in total

Review 1.  Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.

Authors:  Mauricio Burotto; Anish Thomas; Deepa Subramaniam; Giuseppe Giaccone; Arun Rajan
Journal:  J Thorac Oncol       Date:  2014-11       Impact factor: 15.609

2.  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.

Authors:  Gabriella Sozzi; Mattia Boeri; Marta Rossi; Carla Verri; Paola Suatoni; Francesca Bravi; Luca Roz; Davide Conte; Michela Grassi; Nicola Sverzellati; Alfonso Marchiano; Eva Negri; Carlo La Vecchia; Ugo Pastorino
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

3.  miRNA-124 down-regulates SOX8 expression and suppresses cell proliferation in non-small cell lung cancer.

Authors:  Chao Xie; Yunwei Han; Yi Liu; Lei Han; Jie Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.

Authors:  Zhe Zhang; Lu Zhang; Zhi-Yi Yin; Xing-Long Fan; Bo Hu; Lun-Qing Wang; Di Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  MicroRNA-216b regulated proliferation and invasion of non-small cell lung cancer by targeting SOX9.

Authors:  Sida Liu; Han Dong; Hui Dai; Danwei Liu; Zhihao Wang
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

Review 6.  MicroRNAs in endometrial cancer.

Authors:  Kouji Banno; Megumi Yanokura; Iori Kisu; Wataru Yamagami; Nobuyuki Susumu; Daisuke Aoki
Journal:  Int J Clin Oncol       Date:  2013-02-05       Impact factor: 3.402

7.  Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis.

Authors:  Sichuan Xi; Hong Xu; Jigui Shan; Yongguang Tao; Julie A Hong; Suzanne Inchauste; Mary Zhang; Tricia F Kunst; Leandro Mercedes; David S Schrump
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

8.  miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2.

Authors:  Xingyu Lin; Zhiguang Yang; Peng Zhang; Yunpeng Liu; Guoguang Shao
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

9.  MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.

Authors:  Duo Li; Dong-Qiong Li; Dan Liu; Xiao-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2016-01-07       Impact factor: 6.730

10.  microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.

Authors:  Yi Shen; Dongfang Tang; Ruyong Yao; Mingzhao Wang; Yongjie Wang; Yasai Yao; Xiaoxiao Li; Haiping Zhang
Journal:  Med Oncol       Date:  2013-11-06       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.